Abstract: Objective To reflect current cancer treatment effect with real world data based on the follow⁃up data of patients with malignant tumors from a hospital⁃based cancer registry database. Methods The hospitalized patients with malignant tumors diagnosed in the Guangxi Medical University Cancer Hospital from January 1 of 2011 and December 31 of 2020 were enrolled, and a total of 78,046 cases with 17 types of malignant tumors had the follow⁃up data meeting the quality requirements. The survival follow⁃up information was collected from the disease management system records and by telephone visits, and the follow⁃up statistics were conducted as of June 30, 2023. Life table was use to evaluate the 1⁃year, 3⁃year and 5⁃year overall survival (OS) rates of each disease, the survivals of patients with respect to gender, age group, nationality, clinical stages and the first treatment time were analyze. Results The top 5 cancers were liver cancer (14,672 cases), lung cancer (10,878 cases), female breast cancer (9,430 cases), colorectal cancer (6,895 cases) and cervical cancer (6,250 cases). The 1⁃year, 3 year and 5⁃year OS rates of patients with 17 typs of malignant tumors were 76.3%、58.6% and 51.4%, respectively. The 5⁃year OS rate of male patients was lower than that of female patients (39.9% vs 63.1%). The overall trend of OS for each cancer species decreased with increase of age, and the 5⁃year OS rates were 64.0%, 59.6%, 52.7%, 44.9%, and 35.7% for the age groups of ≤44, 45-54, 55-64, 65-74, and ≥75, respectively. Compared with those in the period of 2011—2015, the 5⁃year OS rates of patients with liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer and lymphoma were significantly higher (all P<0.05) during 2016—2020. There was significant difference in survival among patients with different clinical stages of malignant tumors (all P<0.01), and the 5⁃year OS rate of patients with stageⅠ-Ⅱ was higher than that of patients with stage Ⅲ-Ⅳ (82.2% vs 43.4%).The 5⁃year OS rate of patients with liver cancer, lung cancer, female breast cancer, nasopharyngeal carcinoma, colorectal cancer and cervical cancer in Zhuang nationality was significantly lower than that in Han nationality (all P<0.05). Conclusions Liver cancer and lung cancer are the main types of cancer to be treated, and more than 50% of patients with malignant tumors can survive for more than 5 years. The survival status of patients with malignant tumors is significantly different with respect to tumor type, age, gender and nationality. The standardized, innovative, multidisciplinary and precise clinical treatment and the early diagnosis and treatment of cancer should be continuously implemented to further improve the survival of patients.

Key words: Malignant tumor, Survival rate, Hospital-based registry, Follow-up